PMC:7594251 / 82791-83619
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T84 | 61-64 | Disease | denotes | HTS | http://purl.obolibrary.org/obo/MONDO_0011549 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T599 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T600 | 11-12 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T601 | 38-39 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T602 | 87-88 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T603 | 164-165 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T604 | 221-229 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T605 | 372-373 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T606 | 531-539 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T607 | 633-634 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T608 | 782-783 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T62464 | 13-21 | Chemical | denotes | molecule | http://purl.obolibrary.org/obo/CHEBI_25367 |
| T30980 | 482-490 | Chemical | denotes | molecule | http://purl.obolibrary.org/obo/CHEBI_25367 |
| T13331 | 604-608 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T9620 | 701-706 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T33030 | 732-740 | Chemical | denotes | solution | http://purl.obolibrary.org/obo/CHEBI_75958 |
| T2096 | 785-789 | Chemical | denotes | gold | http://purl.obolibrary.org/obo/CHEBI_29287|http://purl.obolibrary.org/obo/CHEBI_30050 |
| T91775 | 813-817 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 825 | 140-144 | Gene | denotes | high | Gene:104137 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T564 | 123-138 | http://purl.obolibrary.org/obo/GO_0016049 | denotes | cellular growth |
| T496 | 132-138 | http://purl.obolibrary.org/obo/GO_0040007 | denotes | growth |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T543 | 0-183 | Sentence | denotes | A “hit” is a molecule identified from a screening technique (HTS, FBDD, etc) as having a desirable effect (i.e., decreased cellular growth, high affinity score) on a target [365,366]. |
| T544 | 184-365 | Sentence | denotes | However, the question of whether the activity is related to actual binding to the target, or to interference with one of the components of the assay readout mechanism, is uncertain. |
| T545 | 366-402 | Sentence | denotes | Thus, a validation step is required. |
| T546 | 403-566 | Sentence | denotes | Hit-validation is therefore the process of confirming, or validating, that the molecule(s) identified previously have on target activity and selectivity [367,368]. |
| T547 | 567-655 | Sentence | denotes | One of the highest-impacts of NMR on drug discovery is the use as a hit-validation tool. |
| T548 | 656-828 | Sentence | denotes | Though the hit-validation or confirmation of drugs is mostly limited to the solution state [369], this aspect of NMR truly is a “gold standard” technique in drug discovery. |